{"url_path":"/sec/taox/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1571934/0001104659-26-060353-index.html","accession_number":"0001104659-26-060353","cik":"0001571934","ticker":"TAOX","issuer_name":"TAO Synergies Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1571934/0001104659-26-060353-index.html","primary_entity_key":"0001571934","primary_entity_name":"TAO Synergies Inc."},"word_count":1092,"has_tables":true,"body_markdown":"TAO Synergies Inc._March 31, 2026\n\n0001571934--12-312026Q1falseTAO Synergies Inc.P3Y0http://fasb.org/us-gaap/2025#UnrealizedGainLossOnInvestments7660037090001571934taox:SeriesBWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-03-310001571934taox:SeriesBWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-03-310001571934taox:SeriesBWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2026-03-310001571934taox:SeriesBWarrantsMembertaox:MeasurementInputEstimatedEquityVolatilityMember2026-03-310001571934taox:SeriesBWarrantsMember2026-03-310001571934taox:SeriesCConvertibleRedeemablePreferredStockMembertaox:September2024PrivatePlacementMember2026-03-310001571934taox:SeriesCConvertibleRedeemablePreferredStockMembertaox:September2024PrivatePlacementMember2025-12-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2025-10-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-03-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-03-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-12-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-12-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMember2025-12-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMember2025-12-310001571934taox:SeriesCConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-03-310001571934taox:SeriesCConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2024-12-310001571934us-gaap:CommonStockMember2026-01-012026-03-310001571934us-gaap:CommonStockMember2025-01-012025-03-310001571934us-gaap:RetainedEarningsMember2026-03-310001571934us-gaap:AdditionalPaidInCapitalMember2026-03-310001571934us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001571934us-gaap:RetainedEarningsMember2025-12-310001571934us-gaap:AdditionalPaidInCapitalMember2025-12-310001571934us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001571934us-gaap:RetainedEarningsMember2025-03-310001571934us-gaap:AdditionalPaidInCapitalMember2025-03-310001571934us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001571934us-gaap:RetainedEarningsMember2024-12-310001571934us-gaap:AdditionalPaidInCapitalMember2024-12-310001571934us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001571934us-gaap:CommonStockMember2026-03-310001571934us-gaap:CommonStockMember2025-12-310001571934us-gaap:CommonStockMember2025-03-310001571934us-gaap:CommonStockMember2024-12-310001571934taox:ShareBasedPaymentArrangementNonemployeeDirectorsMembertaox:DirectorCompensationPolicyMember2025-04-072025-04-070001571934taox:EquityIncentivePlan2020Member2024-12-060001571934taox:EquityIncentivePlan2020Member2024-12-050001571934taox:EquityIncentivePlan2020Member2023-12-200001571934taox:EquityIncentivePlan2020Member2023-12-1900015719342025-08-0600015719342025-08-050001571934taox:ShareBasedPaymentArrangementNonemployeeDirectorsMembertaox:DirectorCompensationPolicyMember2023-03-290001571934taox:ShareBasedPaymentArrangementNewlyAppointedDirectorsMembertaox:DirectorCompensationPolicyMember2023-03-290001571934us-gaap:RestrictedStockMembertaox:ConsultingAgreementWithSherwoodVenturesLlcMember2026-03-062026-03-060001571934us-gaap:RestrictedStockMembertaox:ConsultingAgreementWithSherwoodVenturesLlcMember2026-01-162026-01-160001571934taox:ShareBasedPaymentArrangementNewlyAppointedDirectorsMembertaox:DirectorCompensationPolicyMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-03-292023-03-290001571934taox:ShareBasedPaymentArrangementNewlyAppointedDirectorsMembertaox:DirectorCompensationPolicyMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-03-292023-03-290001571934taox:ShareBasedPaymentArrangementNewlyAppointedDirectorsMembertaox:DirectorCompensationPolicyMember2023-03-292023-03-290001571934taox:ShareBasedPaymentArrangementNonemployeeDirectorsMembertaox:DirectorCompensationPolicyMember2023-03-292023-03-290001571934srt:MinimumMember2026-03-310001571934srt:MaximumMember2026-03-310001571934taox:ConsultingAgreementMember2026-01-012026-03-310001571934taox:ConsultingAgreementMember2025-01-012025-03-310001571934taox:AgreementsWithBryologyxMember2020-06-092020-06-090001571934taox:AgreementsWithBryologyxMember2026-01-012026-03-310001571934us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001571934us-gaap:FairValueInputsLevel3Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001571934us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001571934us-gaap:FairValueInputsLevel3Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2026-03-310001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2026-03-310001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2026-03-310001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2025-12-310001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2025-12-310001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2025-12-310001571934us-gaap:WarrantMembertaox:SeriesBConvertibleRedeemablePreferredStockMember2026-01-012026-03-310001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2026-01-012026-03-310001571934taox:SeriesCWarrantsMemberus-gaap:WarrantMembertaox:SeriesDConvertibleRedeemablePreferredStockMember2026-01-012026-03-310001571934us-gaap:EmbeddedDerivativeFinancialInstrumentsMembertaox:SeriesEConvertibleRedeemablePreferredStockMember2026-01-012026-03-310001571934taox:SeriesBWarrantsMemberus-gaap:WarrantMember2026-01-012026-03-310001571934taox:SeriesBWarrantsMember2026-01-012026-03-310001571934taox:SeriesBWarrantsMember2025-01-012025-03-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2025-01-012025-03-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMembertaox:June2025PrivatePlacementMember2025-03-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-03-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-03-310001571934taox:SeriesCWarrantsMember2026-01-012026-03-310001571934taox:SeriesCWarrantsMember2025-01-012025-03-310001571934us-gaap:SubsequentEventMember2026-05-130001571934taox:UnStakedTaoMember2026-03-310001571934taox:StakedTaoMember2026-03-310001571934us-gaap:LicenseMembertaox:StanfordLicenseAgreementsMember2017-01-192017-01-190001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2026-01-012026-03-310001571934taox:AlanJTuchmanMemberus-gaap:RelatedPartyMember2026-01-012026-03-310001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2025-01-012025-03-310001571934taox:AlanJTuchmanMemberus-gaap:RelatedPartyMember2025-01-012025-03-310001571934taox:SeriesBBrokerWarrantsMember2022-11-1700015719342025-03-3100015719342024-12-310001571934us-gaap:WarrantMember2026-01-012026-03-310001571934us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001571934us-gaap:WarrantMember2025-01-012025-03-310001571934us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001571934us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001571934us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001571934us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001571934us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001571934us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001571934us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001571934taox:Mt.SinaiLicenseAgreementMember2026-03-310001571934taox:Mt.SinaiLicenseAgreementMember2026-02-242026-02-240001571934taox:SeriesCConvertibleRedeemablePreferredStockMembertaox:September2024PrivatePlacementMember2025-01-012025-03-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2026-03-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMembertaox:June2025PrivatePlacementMember2026-03-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMember2026-03-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMember2026-03-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMember2026-01-012026-03-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMember2026-01-012026-03-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2025-10-012025-10-310001571934taox:SeriesCConvertibleRedeemablePreferredStockMembertaox:September2024PrivatePlacementMember2025-01-012025-12-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMember2025-01-012025-12-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMember2025-01-012025-12-310001571934taox:SeriesEConvertibleRedeemablePreferredStockMembertaox:October2025PrivatePlacementMember2026-01-012026-03-310001571934taox:SeriesDConvertibleRedeemablePreferredStockMembertaox:June2025PrivatePlacementMember2026-01-012026-03-310001571934srt:MinimumMembertaox:StanfordLicenseAgreementsMember2017-01-192017-01-190001571934srt:MaximumMembertaox:StanfordLicenseAgreementsMember2017-01-192017-01-190001571934taox:NetSalesUpToDollars250MillionMembertaox:Mt.SinaiLicenseAgreementMember2014-07-142014-07-140001571934taox:NetSalesOverDollarsMillionMembertaox:Mt.SinaiLicenseAgreementMember2014-07-142014-07-140001571934taox:SingleReportableSegmentMember2026-01-012026-03-310001571934taox:SingleReportableSegmentMember2025-01-012025-03-310001571934taox:DanielLAlkonMembertaox:AlkonConsultingAgreementMemberus-gaap:RelatedPartyMember2025-08-090001571934taox:AlanJTuchmanMemberus-gaap:RelatedPartyMember2025-06-080001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2025-06-060001571934taox:DanielLAlkonMembertaox:AlkonConsultingAgreementMemberus-gaap:RelatedPartyMember2025-06-040001571934taox:ConsultingAgreementMember2026-03-310001571934us-gaap:RetainedEarningsMember2026-01-012026-03-310001571934taox:AgreementsWithBryologyxMember2020-06-090001571934taox:SeriesCConvertibleRedeemablePreferredStockMember2025-01-012025-03-310001571934taox:CognitiveResearchEnterprisesIncMember2026-01-012026-03-310001571934taox:ShareBasedPaymentArrangementNonemployeeDirectorsMembertaox:DirectorCompensationPolicyMemberus-gaap:SubsequentEventMember2026-04-072026-04-070001571934taox:Mt.SinaiLicenseAgreementMember2026-01-012026-03-310001571934taox:StanfordLicenseAgreementsMember2014-05-122014-05-120001571934taox:Mt.SinaiLicenseAgreementMember2014-07-142026-03-310001571934taox:YumaSubnetCompositeOnshoreFundL.p.Member2025-10-240001571934taox:YumaLargeCapSubnetOnshoreFundL.p.Member2025-10-240001571934us-gaap:MeasurementInputExpectedTermMembertaox:SeriesCConvertibleRedeemablePreferredStockMembertaox:September2024PrivatePlacementMember2025-01-012025-03-310001571934us-gaap:SubsequentEventMember2026-05-132026-05-130001571934srt:MinimumMember2025-06-012025-06-300001571934srt:MaximumMember2025-06-012025-06-3000015719342025-01-012025-12-310001571934taox:UnStakedTaoMember2026-01-012026-03-310001571934taox:StakedTaoMember2026-01-012026-03-310001571934us-gaap:SubsequentEventMember2026-05-1200015719342025-12-150001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2025-08-142025-08-140001571934taox:JoshuaSilvermanMembertaox:IfTerminationOccursWithin2YearsOr6MonthsPrecedingChangeOfControlMemberus-gaap:RelatedPartyMember2025-08-140001571934taox:JoshuaSilvermanMemberus-gaap:RelatedPartyMember2025-08-140001571934taox:StanfordLicenseAgreementsMember2026-01-012026-03-310001571934taox:NemoursAgreementMember2021-08-052021-08-050001571934taox:NemoursAgreementMember2026-01-012026-03-3100015719342026-03-3100015719342025-12-310001571934taox:StanfordLicenseAgreementsMember2017-01-192017-01-190001571934taox:SeriesCConvertibleRedeemablePreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-03-310001571934us-gaap:RetainedEarningsMember2025-01-012025-03-3100015719342025-01-012025-03-310001571934taox:Mt.SinaiLicenseAgreementMember2014-07-1400015719342026-05-1300015719342026-01-012026-03-31xbrli:sharesiso4217:USDxbrli:puretaox:itemiso4217:USDxbrli:sharestaox:agreementtaox:Votetaox:segmenttaox:Y\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n​\n\n**FORM****10-Q**\n\n​\n\n☒\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\nFor the quarterly period ended March 31, 2026\n\n​\n\nor\n\n​\n\n☐\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n​\n\n​\n\nFor the transition period from __________________ to __________________\n\n​\n\nCommission File Number: **001-40458**\n\n​\n\n**TAO SYNERGIES INC.**\n\n(Exact name of registrant as specified in its charter)\n\n​\n\n**Delaware**\n\n**46-1585656**\n\n(State or other jurisdiction of incorporation or\n\n(I.R.S. Employer\n\norganization)\n\nIdentification No.)\n\n**1185 Avenue of the Americas****,****3rd Floor**\n\n​\n\n**New York****,****New York******\n\n**10036**\n\n(Address of principal executive offices)\n\n(Zip code)\n\n​\n\n**(****973****)****242-0005**\n\n(Registrant’s telephone number, including area code)\n\n​\n\n**Synaptogenix, Inc.**\n\n​\n\n(Former name, former address and former fiscal year, if changed since last report)\n\n​\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\n**Title of each class**\n\n  ​ ​ ​\n\n**Trading Symbol(s)**\n\n  ​ ​ ​\n\n**Name of each exchange on********which registered**\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nCommon Stock, $0.0001 par value per share\n\n  ​ ​ ​\n\nTAOX\n\n  ​ ​ ​\n\nThe Nasdaq Stock Market LLC\n\n​\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐\n\n​\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐\n\n​\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\nEmerging growth company\n\n☐\n\n​\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n​\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒\n\n​\n\nAs of May 13, 2026, there were 7,471,931 shares of the registrant’s common stock, $0.0001 par value per share, issued and outstanding.\n\n​\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION\n\n*Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as “plan,” “anticipate,” “believe,” “estimate,” “should,” “expect” and similar expressions, include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our inability to obtain adequate financing, fluctuations in the price of our digital assets, potential decreases in the value of our digital assets and rewards, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, our inability to expand our business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, volatility in the price of our raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and our failure to implement our business plans or strategies. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. You should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2026, as updated in our quarterly reports and current reports filed with the SEC from time to time. We advise you to carefully review the reports and documents we file from time to time with the SEC including our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under securities laws, we undertake no obligation to publicly release any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.*\n\n​\n\n​\n\n2\n\n[Table of Contents](#TOC)\n\n**TABLE OF CONTENTS**\n\n​\n\nPage\n\n[Part I – FINANCIAL INFORMATION](#PARTI_165600)\n\n4\n\n \n\n[Item 1. Financial Statements (Unaudited)](#Item1FinancialStatements_86564)\n\n4\n\n \n\n[Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025](#BalanceSheets_561547)\n\n4\n\n \n\n[Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2026 and 2025](#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPRE)\n\n5\n\n \n\n[Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2026 and 2025](#Equity_94231)\n\n6\n\n \n\n[Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025](#CashFlows_386858)\n\n7\n\n \n\n[Notes to Condensed Consolidated Financial Statements](#NOTESTOCONDENSEDFINANCIALSTATEMENTS_3081)\n\n8\n\n \n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF)\n\n27\n\n \n\n[Item 3. Quantitative and Qualitative Disclosures about Market Risk](#Item3QuantitativeandQualitativeDisclosur)\n\n35\n\n \n\n[Item 4. Controls and Procedures](#Item4ControlsandProcedures_901954)\n\n35\n\n \n\n[Part II – OTHER INFORMATION](#PARTII_538533)\n\n36\n\n \n\n[Item 1. Legal Proceedings](#Item1LegalProceedings_969762)\n\n36\n\n \n\n[Item 1A. Risk Factors](#Item1ARiskFactors_894724)\n\n36\n\n \n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSalesofEquitySecurities)\n\n36\n\n \n\n[Item 3. Defaults upon Senior Securities](#Item3DefaultsuponSeniorSecurities_455084)\n\n36\n\n \n\n[Item 4. Mine Safety Disclosures](#Item4MineSafetyDisclosures_328331)\n\n36\n\n \n\n[Item 5. Other Information](#Item5OtherInformation_865222)\n\n36\n\n \n\n[Item 6. Exhibits](#Item6Exhibits_669068)\n\n37\n\n \n\n[Signatures](#SIGNATURES_975732)\n\n38\n\n​\n\n​\n\n​\n\n3\n\n[Table of Contents](#TOC)\n\nPART I\n\nFINANCIAL INFORMATION"}